4 results
Phase 2: To evaluate progression-free survival (PFS) as the primary efficacy measure of MLN1117 plus docetaxel versus docetaxel alone in patients with advanced NSCLC
Primary:To determine the safety, tolerability, and pharmacokinetic (PK) profile of single ascending intravenous (iv) doses and of multiple ascending iv doses of FMX-8 in healthy subjectsSecondary:To evaluate the pharmacodynamics (PD) of FMX-8 in…
The effect of the dipeptide alanyl-glutamine, intravenously or enterally and perioperatively given, on postoperative insulin resistance in colon cancer patients.
Aim of the study is to assess the effects of supplemental parenteral L-alanyl-L-glutamine treatment on infectious, cardiac, cerebral, pulmonary and gastro-intestinal morbidity during the ICU- (Intensive Care Unit) and hospital stay in patients after…